Content provided in partnership with

Health Care Industry

Spontaneous vertigo and headache: Endolymphatic hydrops or migraine? - Original Article

Ear, Nose & Throat Journal, Dec, 2001 by Thomas E. Boismier, Michael J. Disher

<< Page 1 Continued from page 3. Previous | Next

References

(1.) Shepard NT, Shepard NP, Boismier T. Fukuda stepping test: Test performance and criteria for abnormal. Presented at the 18th biennial meeting of the Barany Society; Uppsala, Sweden; 1994.

(2.) El-Kashlan HK, Shepard NT. Asher AM, et al. Evaluation of clinical measures of equilibrium. Laryngoscope 1998:108:311-9.

(3.) Jacobson GP. Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg 1990;116:424-7.

(4.) Shepard NT. Telian SA, Smith-Wheelock M. Habituation and balance retraining therapy. A retrospective review. Neurol Clin 1990;8:459-75.

(5.) Johnson GD. Medical management of migraine-related dizziness and vertigo. Laryngoscope 1998:108:1-28.

(6.) Santos PM. Hall RA, Snyder JM, et al. Diuretic and diet effect on Meniere's disease evaluated by the 1985 Committee on Hearing and Equilibrium guidelines. Otolaryngol Head Neck Surg 1993:109:680-9.

(7.) Baloh RW. Honrubia v. Clinical Neurophysiology of the Vestibular System. 2nd ed. Philadelphia: F.A. Davis, 1990:214-9.

(8.) Bikhazi P. Jackson C. Ruckenstein MJ. Efficacy of antimigrainous therapy in the treatment of migraine-associated dizziness. Am J Otol 1997:18:350-4.

(9.) Shepard NT, Telian SA. Practical Management of the Balance Disorder Patient. San Diego: Singular Publishing, 1996.

[Graph omitted]

Figure 1.

Chart illustrates the number (%) of patients who experienced various
outcomes among the 23 patients who were available for assessment at the
first follow-up.


Responded to MAV treatment     n = 6  (26.1%)
Responded to EH treatment      n = 14 (60.9%)
Did not comply with treatment  n = 3  (13.0%)

Note: Table made from pie chart
Table 1.

Mean changes (%) in DHI and symptom scale scores pre- and post-treatment

                    EH group  MAV group  Noncompliant group

DHI (first            -42        -23            +90 (*)
follow-up)
Symptom severity      -54        -44             -5
(first follow-up)
Symptom severity      -47        -42
(second follow-up)

(*)Dizziness Handicap Index scores nearly doubled in the noncompliant
group.
Table 2

Demographic and clinical Characteristics of the two groups

                               EH group              MAV group
                               (n = 14)               (n = 6)

Age range (mean)          13 to 75 yr (52.8)     12 to 55 yr (30.7)
No. female (%)                10 (71.4)               5 (83.3)
No. w/family history           5 (35.7)               3 (50.0)
of migraine (%)
No. w/history of head          4 (28.6)               3 (50.0)
trauma (*) (%)
Duration of vertigo       2 to 72 hr (23.4)       1 to 12 hr (5.3)
attack (mean)
Time from first attack  3 mo to 20 yr (5.5 yr)  2 mo to 5 yr (20 mo)
to DDx (mean)

(*)Includes barotrauma and cranial surgery.

Health Care Industry

Spontaneous vertigo and headache: Endolymphatic hydrops or migraine? - Original Article

Ear, Nose & Throat Journal, Dec, 2001 by Thomas E. Boismier, Michael J. Disher

Find Research Guides for:

Find Featured Titles for: Technology

Most Popular Articles in Health

Most Popular Publications in Health